Stay updated with breaking news from Microsatellite Stable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
22.01.2024 - Agenus Inc. (Nasdaq: AGEN), a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the ... Seite 1
The LEAP-017 trial results presented at ESMO GI 2023 are explored by Dr Marshall.
Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023...
The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.